© 2025 HSP News Service, L.L.C.
Kelly G. Paulson, MD, PhD, of Providence Swedish Cancer Institute (Seattle, WA) and lead of the Center for Immuno-Oncology at Paul G. Allen Research Center, reviews findings from the safety and efficacy data from the phase Ib DeLLphi-303 trial. The study examined tarlatamab, a bispecific T-cell engager, in combination with PD-L1 inhibition as first-line maintenance; the regimen led to unprecedented overall survival results in this patient population, and had an acceptable safety profile (Abstract OA13.01).
Treatment with the viral immunotherapy CAN-2409 helped patients with unresectable, stage III/IV non–small cell lung cancer (NSCLC) continue on immune checkpoint inhibition longer and experience extended survival, despite initial inadequate responses to anti–PD-(L)1 therapy, according to extended...
Resection of the primary thoracic tumor after EGFR tyrosine kinase inhibition demonstrated the ability to prolong disease control in patients with EGFR-mutant metastatic non–small cell lung cancer (NSCLC), according to findings from a randomized phase II trial presented at the International...
Alexander Drilon, MD, presents findings from the phase I/II ARROS-1 trial, which investigated the safety and efficacy of zidesamtinib—an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing—in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC) who experienced disease progression after previous treatment with a TKI (Abstract PL02.15).
Susan C. Scott, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, presents findings from cohort 5 of the phase II PALOMA-2 trial. The data show that subcutaneous administration of the bispecific monoclonal antibody amivantamab-vmjw every 4 weeks, combined with daily receipt of the EGFR TKI lazertinib orally, resulted in high objective response rates among patients with previously untreated EGFR-mutated advanced non–small cell lung cancer (NSCLC) (Abstract MA08.05).
A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (Abstract MA11.09) demonstrated that monitoring circulating tumor DNA (ctDNA) may aid in refining and personalizing the use of consolidation immunotherapy in patients with...
New research has identified interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade. These findings were presented at the...
The presence of tumor spread through air spaces (STAS) demonstrated an association with poor prognosis in patients with early-stage non–small cell lung cancer (NSCLC), whether undergoing segmentectomy or lobectomy, according to findings from an analysis of the phase III JCOG0802/WJOG4607L trial...
A reduced schedule for hypofractionated radiotherapy with concurrent chemotherapy led to numerically similar survival outcomes and a more favorable safety profile compared with a standard course of conventional fractionated radiotherapy for patients with limited-stage small cell lung cancer...
The DLL3-targeted bispecific T-cell engager agent tarlatamab demonstrated significant overall survival in combination with anti‒PD-L1 therapy of either atezolizumab or durvalumab as first-line maintenance therapy for patients with extensive-stage small cell lung cancer (ES-SCLC), according to...
The combination of subcutaneous amivantamab-vmjw every 4 weeks plus daily oral lazertinib led to a high response rate in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to findings from an analysis of cohort 5 of the PALOMA-2 trial presented at ...
Jonathan D. Spicer, MD, PhD, of McGill University Health Centre, discusses health-related quality of life (HRQoL) findings from the CheckMate 77T trial. The analysis determined that receipt of perioperative nivolumab does not result in worse HRQoL outcomes vs placebo in patients with resectable non–small cell lung cancer (NSCLC), regardless of nodal status (Abstract MA04.05).
BMS-986504, a first-in-class agent targeting MTAP, demonstrated antitumor activity in heavily pretreated patients with MTAP-deleted non–small cell lung cancer (NSCLC), according to findings from the phase I/II CA240-0007 trial presented at the International Association for the Study of Lung Cancer...
Video-assisted thoracoscopic surgery (VATS) led to a 21% reduction in the risk of death compared with open lobectomy for patients with early-stage lung cancer, in a meta-analysis of randomized trials comparing the two approaches. Results of the meta-analysis were presented at the International...
Older individuals up to the age of 80 who are eligible for lung surgery may achieve a survival benefit from lung cancer screening comparable to that for younger patients, according to the results of a multicenter cohort study from the United Kingdom presented at the International Association for...
Treating patients who have stage III non–small cell lung cancer (NSCLC) with durvalumab concurrently with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival (OS) compared with consolidation therapy with durvalumab alone, according to research presented...
Interim results from the phase III NADIM ADJUVANT trial, led by the Spanish Lung Cancer Group, suggest that adjuvant chemoimmunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non–small cell lung cancer (NSCLC) while maintaining an acceptable safety...
John M. Varlotto, MD, presents results from the phase III EA5181 trial (from the ECOG-ACRIN Cancer Research Group), which evaluated concurrent and consolidation durvalumab vs consolidation durvalumab alone for patients with unresectable stage III non–small cell lung cancer (NSCLC) (Abstract PL03.04).
Jordi Remon, MD, PhD, of Gustave Roussy, was the invited discussant for the phase III ACROSS 2 study (Abstract PL02.06). Dr. Remon describes the effect of the addition of aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor, to platinum/pemetrexed chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor-suppressor gene mutations.
A first-in-human phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate, demonstrated manageable safety and early signs of antitumor activity in patients with relapsed small cell lung cancer (SCLC). The results were presented at the International...
Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody-drug conjugate, according to data presented at the International Association for the Study of Lung Cancer...
ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...
New results from the phase III ACROSS 2 trial demonstrated that aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), combined with platinum-pemetrexed chemotherapy significantly improved progression-free survival (PFS) compared with aumolertinib monotherapy in patients with...
Treatment with the next-generation ROS1 tyrosine kinase inhibitor (TKI) zidesamtinib led to antitumor activity in patients with ROS1-positive non‒small cell lung cancer (NSCLC) who had experienced disease progression on prior TKI treatments. These findings from the phase I/II ARROS-1 trial were...
The novel antibody-drug conjugate izalontamab brengitecan (also referred to as iza-bren, BL-B01D1) in combination with osimertinib induced a response in all patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and EGFR-sensitizing mutations treated with the combination in ...
The first-in-class EGFR × HER3 bispecific antibody-drug conjugate izalontamab brengitecan (also referred to as iza-bren; BL-B01D1) demonstrated promising efficacy results plus a manageable safety profile in the treatment of patients with previously treated EGFR-mutated non–small cell lung cancer...
Adjuvant treatment with the first-generation ALK inhibitor crizotinib failed to improve disease-free survival outcomes over observation for patients with surgically resected ALK-positive non–small cell lung cancer (NSCLC), according to findings from the phase III E4512 trial presented at the...
A new analysis from the COMPEL trial showed that patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who experienced non–central nervous system (CNS) disease progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based...
An analysis from the phase III CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non–small cell lung cancer (NSCLC), including those with stage III N2 disease. These results were presented at the...
As reported in The Lancet by Barlesi et al, the phase III KRYSTAL-12 trial has shown a significant progression-free survival benefit with adagrasib over docetaxel in patients with previously treated locally advanced or metastatic KRAS G12C–mutated non–small cell lung cancer (NSCLC). Study Details...
“Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB non–small cell lung cancer [NSCLC],” according to Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and ...
In a phase II/III trial (NRG-CC003) reported in the Journal of Clinical Oncology, Gondi et al found that hippocampal avoidance (HA) in prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) did not improve delayed recall failure but was associated with benefits in...
ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...
The main symptom that eventually led to my diagnosis of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) started in the fall of 2009. I was just 17 and in my freshman year at college when I began experiencing a persistent cough. The coughing became so unrelenting over the next month, I...
In patients with newly diagnosed, PD-L1–positive, advanced non–small cell lung cancer (NSCLC) who tested negative for driver mutations, implementation of plasma-guided treatment intensification—from monotherapy with the PD-1 inhibitor pembrolizumab to platinum doublet chemotherapy plus...
Experts from the National Lung Cancer Roundtable have created a customizable, web-based platform that allows groups and local leaders to develop state-based action plans for reducing lung cancer mortality rates. The platform, called the SBI Planning Tool, allows users to explore real-world...
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD)–activating mutations, as...
In patients with small cell lung cancer, second-line treatment with the bispecific T-cell engager tarlatamab-dlle (which targets the delta-like ligand 3 [DLL3]) vs standard-of-care chemotherapy appeared to significantly improve overall survival, progression-free survival, and patient-reported...
Greater consumption of ultraprocessed food is associated with an increased risk of developing either small cell or non–small cell lung cancer, according to findings published in Thorax. "Over the past 2 decades, the consumption of ultraprocessed food has significantly increased worldwide,...
Updated clinical guidelines for the management of patients with early-stage non–small cell lung cancer (NSCLC) from the American College of Chest Physicians (CHEST) recommend use of more minimally invasive procedures and methods where possible. The guidelines, published in the journal CHEST,...
In a 4-year follow-up of the Chinese phase III GEMSTONE-302 trial reported in The Lancet Oncology, Zhou et al examined the survival benefit of adding the PD-L1 inhibitor sugemalimab to first-line platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC) with no...
ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...
ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...
A large prospective cohort study conducted by Ye and Kang et al and published in JAMA Network Open found that, after adjusting for familial and other cancer-related factors, interstitial lung disease (ILD) was associated with an increased risk of developing most histologic subtypes of lung cancer....
Higher ambient exposure to a type of inhalable, fine particulate matter was found to be associated with an increased risk of cancer-related death for patients who were diagnosed with non–small cell lung cancer (NSCLC) while living in California—a state where wildfires are becoming more prevalent,...
The addition of radiation may be able to surmount resistance to immunotherapy for some more immunologically “cold” tumors, as suggested by the findings of a study focused on the immunomodulatory effects of radiation in non–small cell lung cancers (NSCLCs). The research was recently published in...
Positive results from the final overall survival analysis of the phase III FLAURA2 trial showed that osimertinib (a third-generation, irreversible EGFR tyrosine kinase inhibitor) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically...
Linear endobronchial guided sampling of accessible mediastinal lesions is well established as a first-choice modality for lung cancer mediastinal staging. Parenchymal lung lesions, however, are routinely accessed by either a percutaneous (CT-guided) or a bronchoscopic approach. There have been few...
Patients with small cell lung cancer (SCLC) that has metastasized to the brain were safely and successfully treated with targeted stereotactic radiation (SRT) rather than whole-brain radiation therapy (WBRT) in a phase II trial, demonstrating the practicality of a less-invasive approach for...
In a retrospective cohort study reported in JAMA Network Open, Desai et al examined survival outcomes with the addition of immunotherapy to neoadjuvant or adjuvant chemotherapy in patients with resectable non–small cell lung cancer (NSCLC). Study Details The study involved data from the Flatiron...